Bellicum Pharmaceuticals Inc. (BLCM)’s Financial Results Comparing With Intec Pharma Ltd. (NASDAQ:NTEC)

We will be contrasting the differences between Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) and Intec Pharma Ltd. (NASDAQ:NTEC) as far as risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Demonstrates Bellicum Pharmaceuticals Inc. and Intec Pharma Ltd. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows us Bellicum Pharmaceuticals Inc. and Intec Pharma Ltd.’s return on assets, net margins and return on equity.

Analyst Ratings

Bellicum Pharmaceuticals Inc. and Intec Pharma Ltd. Ratings and Recommendations are available in the next table.

Bellicum Pharmaceuticals Inc. has a consensus price target of $19, and a 467.16% upside potential.

Insider Institutional Ownership

Bellicum Pharmaceuticals Inc. and Intec Pharma Ltd. has shares owned by institutional investors as follows: 57.5% and 40.62%. Insiders owned roughly

... read more at: https://hinewulm.com/2019/02/02/bellicum-pharmaceuticals-inc-blcms-financial-results-comparing-with-intec-pharma-ltd-nasdaqntec/

by

Leave a Reply